Published in J Natl Cancer Inst on February 15, 2011
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet (2012) 1.23
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst (2012) 1.04
Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol (2011) 0.91
CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One (2013) 0.90
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet (2015) 0.87
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol (2014) 0.85
A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus (2015) 0.82
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer. Br J Clin Pharmacol (2014) 0.81
Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev (2011) 0.81
Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. Int J Mol Epidemiol Genet (2013) 0.80
Adjuvant Systemic Therapy of Breast Cancer. Breast Care (Basel) (2011) 0.79
Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. Acta Oncol (2011) 0.79
Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. J Natl Cancer Inst (2014) 0.77
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat (2015) 0.76
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. Am J Epidemiol (2016) 0.75
Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study. Acta Oncol (2016) 0.75
Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. PLoS One (2017) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
A comprehensive review of genetic association studies. Genet Med (2002) 16.75
A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol (1995) 9.27
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Fallibility in estimating direct effects. Int J Epidemiol (2002) 8.34
Problems of reporting genetic associations with complex outcomes. Lancet (2003) 8.11
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (2010) 4.73
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol (2007) 3.42
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
Mechanisms of tamoxifen resistance. Endocr Relat Cancer (2004) 2.92
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res (2007) 2.20
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci (2008) 1.95
Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer (2007) 1.94
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol (2008) 1.92
Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst (2008) 1.90
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol (2008) 1.78
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol (2002) 1.75
Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol (2010) 1.66
Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol (2009) 1.65
Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Cancer Epidemiol Biomarkers Prev (2007) 1.57
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol (2007) 1.55
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther (2008) 1.53
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res (2010) 1.49
Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res (1988) 1.45
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol (2007) 1.36
Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat (2007) 1.31
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res (2010) 1.31
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res (2008) 1.28
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol (2002) 1.28
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat (2009) 1.25
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer (2008) 1.22
Using probabilistic corrections to account for abstractor agreement in medical record reviews. Am J Epidemiol (2007) 1.22
Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol (1988) 1.21
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat (2010) 1.18
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids (2007) 1.17
Evaluation of the potential excess of statistically significant findings in published genetic association studies: application to Alzheimer's disease. Am J Epidemiol (2008) 1.13
Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol (2008) 1.09
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol (2010) 1.07
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev (2009) 1.06
Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol (2010) 1.06
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat (2010) 1.03
Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol (2004) 0.98
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2004) 0.96
Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark. Eur J Cancer (2003) 0.94
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res (2010) 0.92
What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer (2006) 0.89
Trends in breast-conserving surgery in Denmark, 1982-2002. Eur J Epidemiol (2007) 0.88
Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol (2008) 0.87
Methodological and statistical issues in pharmacogenomics. J Pharm Pharmacol (2010) 0.84
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Demonstrating stratification in a European American population. Nat Genet (2005) 9.49
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet (2009) 8.42
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
The Danish National Prescription Registry. Scand J Public Health (2011) 6.07
Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ (2006) 5.82
Identifying SNPs predictive of phenotype using random forests. Genet Epidemiol (2005) 5.43
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol (2014) 4.30
Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med (2012) 4.19
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet (2002) 3.82
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 3.70
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet (2007) 3.66
Breast cancer treatment of older women in integrated health care settings. J Clin Oncol (2006) 3.46
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol (2007) 3.42
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology (2006) 3.23
Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol (2007) 3.06
The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol (2009) 3.03
Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. J Clin Oncol (2004) 3.03
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med (2003) 2.81
Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol (2010) 2.80
Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol (2009) 2.79
Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology (2010) 2.77
Meta-analysis of genome-wide association data identifies two loci influencing age at menarche. Nat Genet (2009) 2.58
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf (2010) 2.57
Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat (2006) 2.55
Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol (2010) 2.45
Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg (2007) 2.43
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet (2010) 2.38
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol (2009) 2.33
Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med Genet (2007) 2.32
Non-melanoma skin cancer and ten-year all-cause mortality: a population-based cohort study. Acta Derm Venereol (2010) 2.28
Socioeconomic patient characteristics predict delay in cancer diagnosis: a Danish cohort study. BMC Health Serv Res (2008) 2.28
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst (2011) 2.27
Testing for population subdivision and association in four case-control studies. Am J Hum Genet (2002) 2.26
Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med (2003) 2.24
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med (2006) 2.16
Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension (2008) 2.14
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12
Methodology, design, and analytic techniques to address measurement of comorbid disease. J Gerontol A Biol Sci Med Sci (2007) 2.12
Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol (2011) 2.12
Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol (2007) 2.11
Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol (2010) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J (2009) 2.06
Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol (2014) 2.04
[Do women unnecessarily lose the breast following breast cancer screening?]. Ugeskr Laeger (2003) 2.03
Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J (2013) 2.00
Blood pressure and survival in the oldest old. J Am Geriatr Soc (2007) 1.98
Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol (2012) 1.97
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood (2011) 1.97
Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol (2007) 1.95
Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer (2007) 1.94
Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med (2013) 1.91
Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation (2010) 1.90
Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet (2007) 1.90
Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology (2011) 1.86
Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol (2003) 1.85
Seasonal variation in hospital discharge diagnosis of atrial fibrillation: a population-based study. Epidemiology (2002) 1.85
Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol (2003) 1.83
Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther (2002) 1.82
Acute stress reaction and completed suicide. Int J Epidemiol (2010) 1.82
Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care (2012) 1.82
A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med Genet (2007) 1.81
Performance of random forest when SNPs are in linkage disequilibrium. BMC Bioinformatics (2009) 1.81
Improving quality of care for urban older people with diabetes mellitus and cardiovascular disease. J Am Geriatr Soc (2007) 1.80
Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol (2012) 1.77
Older patients with acute stroke in Denmark: quality of care and short-term mortality. A nationwide follow-up study. Age Ageing (2007) 1.77
Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. J Clin Epidemiol (2002) 1.74
Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer (2012) 1.74
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. Am J Gastroenterol (2013) 1.71
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70
The impact of comorbidity on cancer survival: a review. Clin Epidemiol (2013) 1.68
Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol (2010) 1.66
Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol (2009) 1.65